Trial Profile
A Post Marketing Surveillance to Monitor the Safety of ULTIVA (Remifentanil) Adminstered in Korean Subjects According to the Prescribing Information.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Remifentanil (Primary)
- Indications Postoperative pain
- Focus Adverse reactions
- Sponsors GSK
- 25 Feb 2011 New trial record